Advanced enzyme tech has announced a key leadership change with the resignation of a senior management personnel. The company filed a regulatory disclosure with stock exchanges on March 11, 2026, informing about the departure of Mr. Dipak Roda from his position as Senior Vice President - Marketing and Business Development.

Resignation Details

The resignation was formally tendered on March 10, 2026, and will become effective from the close of business hours on April 09, 2026. This provides the company with a transition period of approximately one month to manage the handover process.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular dated November 11, 2024. Company Secretary and Head – Legal Sanjay Basantani signed the regulatory filing, ensuring compliance with mandatory disclosure requirements.

The company has also uploaded this intimation on its official website at www.advancedenzymes.com , maintaining transparency with stakeholders and ensuring wider accessibility of the information.

Impact on Operations

As Senior Vice President - Marketing and Business Development, Mr. Roda held a key position in the company's commercial operations. The resignation represents a change in the senior management team, though the company has not disclosed details about succession planning or interim arrangements for the role.

Advanced Enzyme Technologies Limited has secured credit ratings from ICRA Limited for its banking facilities totaling ₹100 crore. The company announced the rating assignment to stock exchanges on February 13, 2026, in compliance with SEBI listing regulations.

Credit Rating Details

ICRA Limited assigned ratings across multiple banking instruments for Advanced Enzyme Technologies. The rating actions demonstrate the company's creditworthiness across different facility types.

Banking Facility Breakdown

The ₹40 crore fund-based cash credit facilities are distributed among multiple banking partners. Citibank N.A. provides ₹15 crore, HDFC Bank Limited contributes ₹12.50 crore, and proposed fund-based limits account for the remaining ₹12.50 crore.

For short-term non-fund based facilities worth ₹15 crore, HDFC Bank Limited provides ₹2.50 crore while proposed non-fund based limits constitute ₹12.50 crore. The unallocated limits of ₹45 crore carry dual ratings of [ICRA]AA-(Stable) for long-term and [ICRA]A1+ for short-term components.

Rating Surveillance and Conditions

ICRA Limited specified that the assigned ratings will require surveillance within one year from the rating communication date of February 13, 2026. The rating agency reserves the right to review or revise the ratings based on new information or changing circumstances that could impact the company's creditworthiness.

The ratings are specific to the current terms and conditions of the instruments. Any changes in terms or facility sizes would necessitate a rating review by ICRA. The company must inform ICRA about any defaults, delays in repayment, or significant developments affecting debt servicing capability.

Regulatory Compliance

Advanced Enzyme Technologies fulfilled its disclosure obligations under Regulation 30 of SEBI Listing Regulations by informing both BSE Limited and National Stock Exchange of India about the credit rating assignment. The company also uploaded the rating information on its website at www.advancedenzymes.com for stakeholder access.